Intelsius Launches Extreme Exposure Range to Maintain Sample Integrity

BASEL, Switzerland, January 31, 2012 /PRNewswire/ --

Intelsius, a DGP company, a manufacturer and distributor of temperature-controlled packaging, today announces the launch of the new Xtremotherm™ - Defying Extremes™ range of products.

(Photo: http://photos.prnewswire.com/prnh/20120131/DE44373)

(Logo: http://photos.prnewswire.com/prnh/20101012/DE80101LOGO)

Xtremotherm™ Extreme Exposure Systems range of shipping solutions protects ambient patient samples in extreme climates. Xtremotherm solutions are designed to protect critical patient sample payloads against degradation during periods of extreme temperature exposures that are common during shipment due to increasingly remote clinical sites.   

"The time-sensitive nature of clinical research and extraordinary costs involved in getting a drug or treatment to market, make the Xtremotherm products an excellent choice for extreme temperature environments," said David Walsh, chief executive officer of Intelsius.    

"Xtremotherm products were created to protect the enormous investments made in research and development around the world including emerging markets such as Brazil, China, India and Russia," Walsh said.  As ambient samples are typically not temperature monitored during transport, our Pharma clients can now deploy the best available protection to ensure the sample is viable despite being transported through periods of extreme temperature.  "The loss of a single sample is simply not acceptable from either an ethical or financial perspective. We owe it to the patients to ensure their samples are received at the labs in optimum condition," said Walsh. 

These Intelsius packaging solutions are certified for time ranges from four hours to 38 hours at constant external temperatures of -30 degrees C to +40 degrees C. In particular, Xtremotherm-5 is unique in that it utilizes proprietary patent pending PRA (Peak Ratio Algorithm) Technology™ that delivers the absolute optimal size for maximum performance. "With Phase III per patient clinical trial costs set to reach nearly $50,000, minimizing risk of sample deletion is paramount to study success and hitting deadlines," said Walsh. 

About Intelsius

Incorporated in 1998, Intelsius is a subsidiary of DGP Life Science Ltd. Intelsius specializes in the design, manufacture and supply of temperature-controlled packaging and regulatory-compliant sample transport solutions. With a strong focus on developing environmentally sustainable products and procedures, the company offers eco-friendly ways to ensure the integrity of customers' products and samples. Intelsius is a growing global presence, with manufacturing facilities, distribution hubs and local offices situated throughout the world, including North America, Europe and Asia. For more information, visit http://www.intelsius.com.